Skip to main content
SpringerLink
Log in

Cemiplimab cost-effective first-line therapy for NSCLC with ≥50% expression of PD-L1

  • Unknown
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Regeneron Pharmaceuticals and Sanofi.

  2. incremental cost-effectiveness ratios

Reference

  • Kuznik A, et al. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%. Value in Health : 16 Oct 2021. Available from: URL: https://doi.org/10.1016/j.jval.2021.08.009

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cemiplimab cost-effective first-line therapy for NSCLC with ≥50% expression of PD-L1. PharmacoEcon Outcomes News 890, 4 (2021). https://doi.org/10.1007/s40274-021-08127-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08127-0

Search

Navigation